1. Home
  2. ABVC vs BOLD Comparison

ABVC vs BOLD Comparison

Compare ABVC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ABVC BioPharma Inc.

ABVC

ABVC BioPharma Inc.

HOLD

Current Price

$1.05

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.47

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABVC
BOLD
Founded
2015
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.6M
36.5M
IPO Year
2009
2024

Fundamental Metrics

Financial Performance
Metric
ABVC
BOLD
Price
$1.05
$1.47
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
151.7K
425.5K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
7.14
32.47
EPS
N/A
N/A
Revenue
$509,589.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.96
52 Week High
$4.02
$1.78

Technical Indicators

Market Signals
Indicator
ABVC
BOLD
Relative Strength Index (RSI) 36.72 60.13
Support Level $0.88 $1.08
Resistance Level $1.71 $1.55
Average True Range (ATR) 0.14 0.09
MACD -0.02 0.01
Stochastic Oscillator 7.14 63.39

Price Performance

Historical Comparison
ABVC
BOLD

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: